Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-28 02:33:08 - browse：512

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

knowledge

WSS

The Readout: Gilead, Bernie Sanders, and other pharma news

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

The new shift in health care is toward less care

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

FDA approves potent Eli Lilly obesity drug, Zepbound

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

In Memoriam: Notable people who died in 2023

Industry veterans launch new biotech VC with $310M

Novavax promises a turnaround & Lilly roils the obesity market

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Supreme Court strikes down use of affirmative action

A clever new way to fix Medicaid and graduate medical education

Medicare proposal to cover medical devices draws a mixed reaction

The Readout: Gilead, Bernie Sanders, and other pharma news

What does generative AI mean for health care? We asked experts

Readout LOUD podcast: How biotech is using artificial intelligence

knowledge

Diversify hospital leadership teams to protect BIPOC patient health

A disappointing year of Humira biosimilars

Biden report: The neurospychology of memory and aging

What we’ve learned from the Aduhelm mess

Biotech incubator Curie.Bio graduates its first startup

More doctors should go into startup world

knowledge

leisure time

focus

hotspot